[go: up one dir, main page]

MX2023009728A - Vacuna recombinante meningococica b. - Google Patents

Vacuna recombinante meningococica b.

Info

Publication number
MX2023009728A
MX2023009728A MX2023009728A MX2023009728A MX2023009728A MX 2023009728 A MX2023009728 A MX 2023009728A MX 2023009728 A MX2023009728 A MX 2023009728A MX 2023009728 A MX2023009728 A MX 2023009728A MX 2023009728 A MX2023009728 A MX 2023009728A
Authority
MX
Mexico
Prior art keywords
protein
meningococcal
fhbp
antigens
present disclosure
Prior art date
Application number
MX2023009728A
Other languages
English (en)
Inventor
Laurence Quemeneur
Nadège Arnaud-Barbe
Vinod Balhara
Raffaella Iantomasi
Marie- Pierre Kazek-Duret
Jacqueline Mccluskey
Bachra Rokbi
John SHIVER
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of MX2023009728A publication Critical patent/MX2023009728A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/36—Neisseria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción se refiere a una composición inmunógena que comprende una combinación de antígenos meningocócicos que comprende al menos una proteína de unión al factor H proteína A (fHBP), al menos una proteína fHBP B, al menos una proteína adhesina A de Neisseria (NadA), y al menos una vesícula de membrana externa extraída con detergente (dOMV). Los antígenos meningocócicos pueden ser de Neisseria meningitidis del serogrupo B. La combinación de antígenos proporcionaba una amplia cobertura de cepas bacterianas. Además, la presente descripción se refiere al uso de la composición inmunógena en métodos para producir una respuesta inmunitaria.
MX2023009728A 2021-02-19 2022-02-18 Vacuna recombinante meningococica b. MX2023009728A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21305211 2021-02-19
US202163172885P 2021-04-09 2021-04-09
PCT/US2022/016894 WO2022178196A1 (en) 2021-02-19 2022-02-18 Meningococcal b recombinant vaccine

Publications (1)

Publication Number Publication Date
MX2023009728A true MX2023009728A (es) 2023-08-30

Family

ID=80595537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009728A MX2023009728A (es) 2021-02-19 2022-02-18 Vacuna recombinante meningococica b.

Country Status (11)

Country Link
US (2) US12053516B2 (es)
EP (1) EP4294432A1 (es)
JP (1) JP2024507828A (es)
KR (1) KR20230147075A (es)
AU (1) AU2022223712A1 (es)
CA (1) CA3211240A1 (es)
CO (1) CO2023010612A2 (es)
IL (1) IL305313A (es)
MX (1) MX2023009728A (es)
TW (1) TW202245836A (es)
WO (1) WO2022178196A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
WO2025126019A1 (en) * 2023-12-13 2025-06-19 Pfizer Inc. Rna molecules

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
PT761231E (pt) 1992-06-25 2000-06-30 Smithkline Beecham Biolog Composicao de vacina contendo adjuvantes
US5776468A (en) 1993-03-23 1998-07-07 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5494808A (en) 1994-09-15 1996-02-27 Merck & Co., Inc. Defined medium OMPC fermentation process
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
CA2301575C (en) 1997-05-20 2003-12-23 Ottawa Civic Hospital Loeb Research Institute Vectors and methods for immunization or therapeutic protocols
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
ES2298316T3 (es) 1997-09-05 2008-05-16 Glaxosmithkline Biologicals S.A. Emulsiones de aceite en agua que contienen saponinas.
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
DE60038166T2 (de) 1999-03-19 2009-03-12 Glaxosmithkline Biologicals S.A., Rixensart Impfstoff gegen bakterielle antigene
CZ303515B6 (cs) 1999-04-19 2012-11-07 Smithkline Beecham Biologicals S. A. Adjuvantní prostredek
CZ20021045A3 (cs) 1999-09-24 2002-08-14 Smithkline Beecham Biologicals S. A. Pomocný prostředek
HUP0202885A3 (en) 1999-09-24 2004-07-28 Smithkline Beecham Biolog Vaccines
RU2304617C2 (ru) 2000-02-28 2007-08-20 Новартис Вэксинс Энд Диагностикс С.Р.Л. Гибридная экспрессия белков neisseria
CA2435681C (en) 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
AU2009221180B2 (en) 2008-03-05 2014-02-13 Sanofi Pasteur Process for stabilizing an adjuvant containing vaccine composition
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
AU2016273825A1 (en) * 2009-10-27 2017-01-05 Novartis Ag Modified meningococcal fHBP polypeptides
CN103002910A (zh) * 2010-03-10 2013-03-27 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
BR122021020829B8 (pt) 2010-03-30 2022-12-27 Children´S Hospital & Res Center At Oakland Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
WO2011161653A1 (en) * 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
JP5976652B2 (ja) 2010-09-10 2016-08-24 ワイス・エルエルシー 髄膜炎菌ｏｒｆ２０８６抗原の非脂質化変異体
JP6042816B2 (ja) 2011-09-26 2016-12-14 テルモ株式会社 液体注入具
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
AU2014296027A1 (en) 2013-08-02 2016-02-04 Children's Hospital & Research Center At Oakland Non-naturally occurring factor H binding proteins (fHbp) and methods of use thereof
SMT202000704T1 (it) 2014-02-28 2021-01-05 Glaxosmithkline Biologicals Sa POLIPEPTIDI DI fHbp DI MENINGOCOCCO MODIFICATI
EP3127572B1 (en) 2014-03-31 2021-12-22 Terumo Kabushiki Kaisha Prefilled syringe
BE1022641B1 (fr) 2014-07-17 2016-06-23 Glaxosmithkline Biologicals Sa POLYPEPTIDES MENINGOCOCCIQUES fHbp MODIFIES
BR112017001417B1 (pt) 2014-07-23 2023-11-07 Children's Hospital & Research Center At Oakland Variantes da proteína de ligação ao fator h (fhbp), composição imunogênica e uso de uma fhbp variante referência cruzada
EP3011990A1 (en) 2014-10-21 2016-04-27 Sulzer Mixpac AG Dual-chamber syringe
HRP20240433T1 (hr) 2016-09-02 2024-07-05 Sanofi Pasteur, Inc. Cjepivo protiv neisseria meningitidis
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
CA3129425A1 (en) * 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Also Published As

Publication number Publication date
US20240415948A1 (en) 2024-12-19
KR20230147075A (ko) 2023-10-20
CA3211240A1 (en) 2022-08-25
AU2022223712A9 (en) 2024-02-22
US20220265805A1 (en) 2022-08-25
TW202245836A (zh) 2022-12-01
JP2024507828A (ja) 2024-02-21
WO2022178196A1 (en) 2022-08-25
EP4294432A1 (en) 2023-12-27
US12053516B2 (en) 2024-08-06
CO2023010612A2 (es) 2023-09-08
IL305313A (en) 2023-10-01
AU2022223712A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
Nieves et al. A Burkholderia pseudomallei outer membrane vesicle vaccine provides protection against lethal sepsis
Sanders et al. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines
CY1117957T1 (el) Συμπληρωμενο omv εμβολιο εναντι μηνιγγιοκοκκου
NZ595291A (en) Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
MX2023009728A (es) Vacuna recombinante meningococica b.
JP7337107B2 (ja) 髄膜炎菌（Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
NO20071609L (no) Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker
JP2004512269A5 (es)
JP2011500662A5 (es)
JP2014503172A5 (es)
EP4056198A3 (en) Outer membrane vesicles
RU2007128332A (ru) Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
EP2544714A1 (en) Vaccine composition
JP2019167368A (ja) 髄膜炎菌（Ｎｅｉｓｓｅｒｉａ ｍｅｎｉｎｇｉｔｉｄｉｓ）組成物およびその方法
PH12013500453B1 (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
HRP20120433T1 (en) Meningococcal vaccine formulations
WO2008102173A1 (en) Compositions comprising polysaccharide conjugates and their use as vaccines
GB2434367A (en) Improved vaccines
JP2002537352A5 (es)
AU2008327827A1 (en) Bluetongue virus vaccine and immunogenic compositions, methods of use and methods of producing same
Zhang et al. Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification
Fukasawa et al. Adjuvant can improve protection induced by OMV vaccine against Neisseria meningitidis serogroups B/C in neonatal mice
MX2023002081A (es) Composiciones vacunales contra el virus sars-cov-2 basadas en un dimero del dominio de union al receptor y la vesicula de membrana externa del meningococo b.
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use